Fungal infections in patients with progressing COVID-19: pathomorphology and description of clinical cases

Invasive pulmonary mycoses are a common complication of severe COVID-19 (COronaVIrus Disease 2019) and are characterized by rapid spread and high mortality. It is especially important to study the epidemiology and pathomorphology of fungal superinfection in order to understand the main vector of the diagnosis and treatment of this complication. The aim of this paper is to consider aspects of the epidemiology, pathomorphologic picture, and clinical manifestations of invasive pulmonary mycoses associated with COVID-19. Clinical cases of fungal superinfections (candidiasis, aspergillosis) associated with COVID-19 in patients receiving appropriate therapy were presented. Results of autopsy examination and light microscopy with routine staining were analyzed. Macroscopic assessment of lesions and histological examination revealed morphological multiorgan changes typical of the combination of fungal (candidiasis, aspergillosis) and viral infection (COVID-19). Conclusion. The presented data of post-mortem examination are important for both science and clinical practice as they form the basis for finding new ways of treating patients with comorbid pathology and developing a prognostic algorithm.

1. Khostelidi C.N., Shadrivova O.V., Borzova Yu.V. [Clinical and laboratory features of mucormycosis in adults]. Problemy meditsinskoy mikologii. 2020; 22 (2): 22–28. DOI: 10.24412/1999-6780-2020-2-22-28 (in Russian).

2. Gangneux J.P., Bougnoux M.E., Dannaoui E. et al. Invasive fungal diseases during COVID-19: We should be prepared. J. Mycol. Med. 2020; 30 (2): 100971. DOI: 10.1016/j.mycmed.2020.100971.

3. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI: 10.1016/S2213-2600(20)30079-5.

4. Sen M., Honavar S.G., Bansal R. et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J. Ophthalmol. 2021; 69 (7): 1670–1692. DOI: 10.4103/ijo.IJO_1565_21.

5. Ramaswami A., Sahu A.K., Kumar A. et al. COVID-19-associated mucormycosis presenting to the Emergency Department-an observational study of 70 patients. QJM. 2021; 114 (7): 464–470. DOI: 10.1093/qjmed/hcab190.

6. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int [Accessed: April 04, 2023].

7. Chestnova T.V., Podshibyakina A.S. [Association of SARS-CoV-2 with bacterial, viral and fungal pathogens as a possible cause of severe forms of COVID-19]. Vestnik novykh meditsinskikh tekhnologiy. 2022; 28 (3): 58–63. DOI: 10.24412/1609-2163-2021-3-58-63 (in Russian).

8. Arastehfar A., Carvalho A., van de Veerdonk F.L. et al. COVID-19-associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J. Fungi (Basel). 2020; 6 (2): 91. DOI: 10.3390/jof6020091.

9. Ovsyannikov N.V., Bilevich O.A. [COVID-19-associated pulmonary aspergillosis]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2021; 23 (3): 239–246. DOI: 10.36488/cmac.2021.3.239-246 (in Russian).

10. Kostinov M.P., Markelova E.V., Svitich O.A., Polishchuk V.B. [Immune mechanisms of SARS-CoV-2 and potential drugs in the prevention and treatment of COVID-19]. Pul'monologiya. 2020; 30 (5): 700–708. DOI: 10.18093/0869-0189-2020-30-5-700-708 (in Russian).

11. Wang J., Yang Q., Zhang P. et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit. Care. 2020; 24 (1): 299. DOI: 10.1186/s13054-020-03046-7.

12. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223): 507–513. DOI: 10.1016/S0140-6736(20)30211-7.

13. Shadrivova O.V., Kozlova O.P., Desyatik E.A. [A clinical case of invasive aspergillosis of lungs on the background of the us of tumor necrosis factor-alpha inhibitor]. Problemy meditsinskoy mikologii. 2016; 18 (4): 23–26. Available at: https://cyberleninka.ru/article/n/klinicheskiy-sluchay-invazivnogo-aspergilleza-legkih-na-fone-primeneniya-ingibitora-faktora-nekroza-opuholi-alfa/viewer (in Russian).

14. van Arkel A.L.E., Rijpstra T.A., Belderbos H.N.A. et al. COVID-19-associated pulmonary aspergillosis. Am. J. Respir. Crit. Care Med. 2020; 202 (1): 132–135. DOI: 10.1164/rccm.202004-1038LE.

15. Tilavberdiev Sh.A., Madaminov F.A., Tursumetov A.A. et al. [A clinical case of successful treatment of associated with COVID-19 invasive aspergillosis in the Republic of Uzbekistan]. Problemy meditsinskoy mikologii. 2022; 24 (2): 12–15. DOI: 10.24412/1999-6780-2022-2-12-15 (in Russian).

16. Charlson E.S., Diamond J.M., Bittinger K. et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am. J. Respir. Crit. Care Med. 2012; 186 (6): 536–545. DOI: 10.1164/rccm.201204-0693OC.

17. Arastehfar A., Carvalho A., Nguyen M.H. et al. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions. J. Fungi (Basel). 2020; 6 (4): 211. DOI: 10.3390/jof6040211.